Skip to content

To assess the efficacy of anti-wrinkle products.

To assess the efficacy, quality of life and safety of IDCTM (Integral Dermo Correction) products in patients with wrinkles on the face

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2012/04/002551
Enrollment
100
Registered
2012-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Wrinkles on face and neck

Interventions

Intervention1: IDC- Anti wrinkle creams ANTI-WRINKLE AND FIRMING (AWF) for Women ANTI-WRINKLE AND FIRMING (AWF) for Men DEEP WRINKLES : Appropriate amount to be applied affected area or over face and

Sponsors

Glenmark Pharmaceuticals Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with wrinkles (Class 1 to 3) Age group (AWF â?? Women: 35 to 50 yrs; AWF â?? Men: 35 years and above; Deep wrinkles : 35 yrs and above) Willing to restrain from prolonged exposure to the sun for the length of the study Available for the entire duration of the study

Exclusion criteria

Exclusion criteria: Hypersensitivity to any ingredients Pregnant and lactating women. Subjects who are applying anti-aging anti-wrinkle or AHA (Alpha hydroxy acids) based or retinol based cosmetics or have applied any of these in the last 3 months. Subjects with dermatological disorder of face that may interfere with study evaluation. Subjects who have undergone any surgical treatment of the face

Design outcomes

Primary

MeasureTime frame
Improvement in Class of Wrinkle according to MFWS Scale Timepoint: 12 weeks

Secondary

MeasureTime frame
Physicians Global Assessment Grade for improvement in wrinkles Patients Global Assessment Grade for improvement in wrinkles Quality of life Patient Satisfaction Questionnaire Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Amanjit Ahluwalia

Glenmark Pharmaceuticals Limited

amanjita@glenmarkpharma.com408889084

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026